IN THE MATTER OF

MEAGAN JACKSON, PHARM TECH

Registration No.: T07985

Respondent

BEFORE THE

STATE BOARD

OF

PHARMACY

Case No. PT-15-019

ORDER FOR SUMMARY SUSPENSION

Pursuant to Md. State Gov't (SG) Code Ann. §10-226(c)(2) (2014 Repl. Vol. II), the State Board of Pharmacy (the "Board") hereby suspends the registration to practice as a Pharmacy Technician (Pharm Tech) in Maryland issued to MEAGAN JACKSON, (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md. Health Occ. (HO) Code Ann. §§ 12-101 et seq. (2014 Repl. Vol. II.). This Order is based on the following investigative findings, which the Board has reason to believe are true:

INVESTIGATIVE FINDINGS

1. At all times relevant hereto, the Respondent was registered to practice as a Pharm Tech in Maryland. The Respondent was first registered on September 2, 2010. The Respondent's registration expires on March 31, 2016.

HOSPITAL A

2. The Respondent was employed as a Pharm Tech at a medical center in Baltimore, Maryland, hereinafter "Hospital A." The Board's investigation revealed the following:

1The names of facilities are confidential. The Respondent may obtain the names by contacting the Administrative Prosecutor.
A. By letter dated February 9, 2015, Hospital A notified the Board that the Respondent had been terminated from employment for “reporting to work while impaired by or under the influence of any intoxicant, hallucinogenic, or narcotic, or where the presence of any such substance has been established by a ‘For Cause drug test’";

B. Hospital A discovered irregularities in records for oxycodone\(^2\) tablets in May and August of 2014 which led to an investigation by its corporate security personnel;

C. On or about November 6, 2014 a nurse at Hospital A reported a bottle of oxycodone liquid appeared to have been tampered with inasmuch as it was open, over-filled, and was a lighter color than normal, appearing to be diluted;

D. Adequate documentation existed of the Respondent’s involvement to support a “For Cause” testing to be initiated by Hospital A;

E. Hospital A removed the bottles of oxycodone liquid from the shelves and sent them to a lab for testing, which revealed that the bottles were only 16% of the labelled potency;

F. Had Hospital A not removed the bottles, Hospital A patients would have received sub-therapeutic doses of pain medication.

G. On or about January 14, 2015, Hospital A notified the Respondent that her drug test came back positive and, therefore, she was terminated from employment.

\(^2\)Oxycodone treats moderate to severe pain.
H. Hospital A submitted two Drug Enforcement Administration "Report(s) of Theft or Loss of Controlled Substances" pertaining to the Respondent, as follows:

(1) The report indicates that 20 oxycodone HCL, 5 mg tablets were stolen, which Hospital A did not report because of the insignificance vis-à-vis the total inventory until that disappearance was linked to subsequent findings;

(2) Hospital A reported that 1140 ml of oxycodone HCL 5mg ml sol was stolen by the Respondent who diluted the drugs.

**HOSPITAL B**

3. While subsequently employed as a Pharm Tech at Hospital B, Hospital B reported the following

A. On or about May 5, 2015, Hospital B filed a report with the Board indicating that the Respondent had "resigned" after she was found to be diverting Oxycontin\(^3\) 40 mg SR (19 tablets) and Oxycontin IR 15 mg (5 tablets) over the past four weeks;

B. Hospital B filed the DEA report as required, submitting the list of drugs stolen and stating that the loss was due to employee pilferage.

**CONCLUSIONS OF LAW**

Based on the foregoing, the Board finds that the public health, safety or welfare imperatively requires emergency action, pursuant to SG §10-226(c)(2).

---

\(^3\)OxyContin is a form of oxycodone that treats moderate to severe pain when around the clock pain relief is needed, as doses are taken every 12 hours as a slow release.
ORDER

Based on the foregoing, it is therefore this 29th day of May 2015, by a majority vote of a quorum of the State Board of Pharmacy, by authority granted to the Board by SG §10-226(c)(2), the registration held by the Respondent to practice as a Pharm Tech in Maryland, Registration No. T07985, is hereby SUMMARILY SUSPENDED; and be it further

ORDERED that, upon the Board's receipt of a written request from the Respondent, a Show Cause Hearing shall be scheduled within a reasonable time of said request, at which the Respondent will be given an opportunity to be heard as to whether the Summary Suspension should be continued, regarding the Respondent's fitness to practice as a Pharm Tech and the danger to the public; and be it further

ORDERED, that the Respondent shall immediately turn over to the Board her wall certificate and wallet-sized registration to practice as a Pharm Tech issued by the Board; and be it further

ORDERED that this document constitutes a final Order of the Board and is, therefore, a public document for purposes of public disclosure, as required by Md. General Provisions Code Ann. §§ 4-101 et seq. (2014 Vol.).

Lenna Isradian-Jamgeehian, PharmD.
President
Board of Pharmacy

NOTICE OF HEARING

A Show Cause hearing to determine whether the Summary Suspension shall be continued will be held before the Board at 4201 Patterson Avenue, Baltimore, 21215 following a written request by the Respondent for same.